Bispecific Antibody

Bispecific Antibody

Bispecific antibodies are engineered molecules that can bind to two different targets simultaneously. They're designed to redirect immune cells to target specific cells, such as cancer cells, enhancing the body's ability to fight diseases. These antibodies have gained attention in cancer therapy and other fields due to their potential to improve treatment efficacy and reduce side effects. A rising number of clinical trials and technological advancements to find effective treatments are leading to the market's growth. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are driving the bispecific antibody market globally.

The Bispecific Antibody Market is expected to grow at a steady rate of around 11.2% owing to the rising drug approvals. For instance, in October 2022, Tecvayli, a bispecific antibody therapy targeting B-cell maturation antigen and CD3, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat myeloma that persisted after four or more lines of prior therapy. Several factors, including rising investments in healthcare departments, are driving the market's growth during the forecast period. Apart from this, the accelerated launch of bispecific antibodies has resulted in higher demand for effective treatment procedures which are also driving this market of bispecific antibodies at a steady rate.

• Based on the drug type, the market is segmented into blinatumomab, emicizumab, amivantamab, and others. The blinatumomab segment dominated the market in the year 2022 owing to the rising product approvals. For instance, in June 2023, Amgen received the U.S. Food and Drug Administration (FDA) for its supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) for the treatment of adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia. Blinatumomab is a novel immunotherapy drug used in the treatment of certain types of leukemia. Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct. It works by binding simultaneously to CD19, a protein found on the surface of B cells, and CD3, a protein found on the surface of T cells. By bringing T cells into proximity to cancerous B cells, blinatumomab activates the T cells, which then target and destroy the cancer cells. Thus, among the drug types, the blinatumomab segment held a significant market share in 2022.
• Based on the indication, the market is categorized into cancer, hemophilia, macular degeneration, and others. The hemophilia segment is expected to hold a significant share of the market in the forecast period owing to the rising clinical studies for treating hemophilia. For instance, in July 2021, JW Pharmaceutical initiated a clinical trial to evaluate the safety, efficacy, and pharmacokinetics of FVIII Inhibitor titers of Hemlibra subcutaneous injection in Korean Hemophilia A patients with/without FVIII Inhibitors. The hemophilia segment in the bispecific antibody market focuses on developing novel therapeutic approaches to treat hemophilia, a genetic bleeding disorder characterized by deficiencies or defects in clotting factors. Hemophilia is traditionally treated with replacement therapy, where the deficient clotting factor is administered intravenously to prevent or control bleeding episodes. Bispecific antibodies offer a potential alternative or complementary therapy for hemophilia patients, addressing some of these unmet medical needs. Thus, the hemophilia category will witness a higher CAGR amongst end users during the forecast period.
• For a better understanding of the market adoption of behcet’s disease therapeutics, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the surge in cases of cancer, rising healthcare expenditure, and rising initiatives and investments in introducing innovative advancements. For instance, in May 2023, U.S-based AbbVie received U.S. Food and Drug Administration (FDA) approval for its EPKINLYTM as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Government organizations are initiating awareness programs for chronic diseases for the sake of the growing cases in the region. Thus, amongst regions, North America held a significant share of the market in 2022.
• Some of the major players operating in the market include Akeso Biopharma Co., Ltd.; Alexion Pharmaceuticals, Inc.; Amgen Inc.; Genmab A/S; Immunocore Ltd.; Janssen Global Services, LLC; Linton Pharm; Merck KGaA; Genentech, Inc.; Pfizer Inc.